ArticleFrontiers in immunology2021
Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Investigating health related quality of life and clinical measures in autoimmune encephalitis: a systematic review.Orphanet journal of rare diseases · 2025Pooled it
- Evaluation of the clinical assessment scale for autoimmune encephalitis (CASE) in a retrospective cohort and a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Immune context and treatment timing associated with seizure freedom after rituximab in autoimmune limbic encephalitis.iScience · 2026Article
- FDG-PET Associations With Disease Severity and Outcomes in NMDA-Receptor IgG Autoimmune Encephalitis.Annals of clinical and translational neurology · 2026Article
- Anti-NMDA receptor encephalitis outcomes in a population-based cohort.Journal of neurology · 2026Article
- Minimally Clinically Important Difference of the Clinical Assessment Scale in Autoimmune Encephalitis.Annals of clinical and translational neurology · 2026Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Cerebral Cortical Encephalitis: A Comparative Study With Antibody-Negative and Non-MOG Antibody-Positive Cortical Encephalitis in Chinese Adults.CNS neuroscience & therapeutics · 2026Article
- Antineuronal antibody titres in autoimmune encephalitis: clinical implications for diagnosis and long-term immunotherapy.Frontiers in immunology · 2026Article
- Early prediction of severe autoimmune encephalitis: development and validation of a model incorporating readily available lactate dehydrogenase.Frontiers in immunology · 2026Article
- Longitudinal changes in [European journal of nuclear medicine and molecular imaging · 2026Article
- Early psychiatric manifestations in pediatric autoimmune encephalitis: clinical data from a tertiary center.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Observational
- Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium.Journal of neurology · 2025Article
- Machine Learning and Shapley Additive Explanations Value Integration for Predicting the Prognostic of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Model Development and Evaluation Study.JMIR medical informatics · 2025Article
- Capturing what matters: Patient-reported LGI1-ANTibody encephalitis outcome RatiNg scale (LANTERN).Annals of clinical and translational neurology · 2025Article
- Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.Journal of neurology · 2025Article
- Seizures and status epilepticus in anti-NMDA receptor encephalitis.Journal of neurology · 2025Article
- Cerebrospinal fluid biomarkers for predicting immunotherapy response in autoimmune encephalitis.American journal of translational research · 2025Article
- Assessment of clinical prognosis in autoimmune encephalitis: Girona score.Frontiers in psychiatry · 2025Article
- The clinical value of the neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, monocyte-to-lymphocyte ratio and platelet-to-lymphocyte ratio for predicting the severity of patients with autoimmune encephalitis.Frontiers in neurology · 2025Article
- Prediction model for severe autoimmune encephalitis: a tool for risk assessment and individualized treatment guidance.Frontiers in neurology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Methods: Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Results: Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p<0.001). Twenty-two patients had poor functional status (mRS>2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p<0.001). Sixty patients were admitted to the intensive care unit (ICU), and the CASE scores were positively correlated with days in the ICU (r=0.58, p<0.001). There was no statistically significant association between the CASE scores and relapse (p=0.39>0.05). Additionally, the CASE scores were positively associated with the mRS scores (r=0.85 p<0.001). Conclusions: The CASE score is suitable for the comprehensive assessment of Chinese patients with autoimmune encephalitis, which may help clinicians to select the appropriate intervention and estimate the disease severity and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.